CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management

NCT06804395 | Recruiting

• 1 other identifier: Pro2024-0211
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

Early diagnosis of cancer allows for better treatment outcomes, higher survival rates, and lower costs of care. It is shown that cancer monitoring for cancer in at-risk populations is a key component in early diagnosis. The HMH Hennessey Institute for Cancer prevention and Applied Molecular Science (HICAP) is a newly founded institute, providing clinical services for cancer screening and risk assessment to the community, as well as research in cancer risk and prevention. The CanScan registry will prospectively collect data from participants in the form of questionnaires. The registry will also capture data that is collected as per non-research assessments, for participants who consent to participate. The registry will facilitate better understanding of cancer risk, screening, and diagnostics.

Conditions

Cancer Risk

Keywords

Cancer Prevention; Cancer Risk; Cancer Early Detection; Cancer High Risk

Outcome Measures

Primary Outcomes (1)

• Rate of Pathogenic Germline Variants (PGV)

  Compare the number of detected PGVs as measured by a universal multi-gene panel, proactively, in a diverse community-based population of individuals. PGV rate will be compared to NCCN genetic testing criteria at baseline, and to longitudinal cancer outcomes.

  10 years from study initiation as defined based on the date the first patient was enrolled.

Secondary Outcomes (4)

• Incidence of Cancer

  10 years from study enrollment.

• Genetic Risk Score (GRS)

  10 years from study enrollment

• Environmental and Lifestyle Factors

  10 years from study enrollment

• Impact of Early Detection and Prevention on Cancer Outcomes

  10 years from study enrollment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Individuals who are at risk for cancer or who have taken the Hennessy Institute cancer risk assessment (I.e participated in their cancer prevention program)

* Adults ( 18 and older) * Ability to provide own consent * Must meet at least one of the below criteria, Indicating an increased risk for cancer, any of the following: * Family or personal history suggests a familial/hereditary disorder known or suspected of predisposition to cancer. * Personal factors associated with an increased risk for cancer include benign breast disease, polyps, tobacco use, etc.as defined by the investigator. * Family members of participating individuals. * Any participant in the HICAP program regardless of cancer risk

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Hackensack Meridian Health: lead

Study Sites (1)

Hennessy Institute for Cancer Prevention and Applied Molecular Medicine

Totowa, New Jersey, 07462, United States

RECRUITING

Study Officials

• Elias Obeid, MD, MPH

  Hackensack Meridian Health

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lee Ifhar, MSc, CCRP

CONTACT

862-657-4227; Lee.ifhar@hmhn.org

Renata Castro, MS

CONTACT

Renata.Castro@hmh.org

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 17, 2025
• First Posted: February 3, 2025
• Study Start: October 1, 2024
• Primary Completion (Estimated): October 1, 2034
• Study Completion (Estimated): October 1, 2034
• Last Updated: August 19, 2025

Record last verified: 2025-08

Locations

US (1)